The future role of monoclonal antibody therapy in childhood acute leukaemias

British Journal of Haematology

Volumn 159, Issue 1, 2012, Pages 3-17

  Barth, Matthew ^a   Raetz, Elizabeth ^b   Cairo, Mitchell S ^c  

^a UNIVERSITY AT BUFFALO   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Monoclonal antibodies

Indexed keywords

ALEMTUZUMAB; ASPARAGINASE; BLINATUMOMAB; CARBOPLATIN; CARMUSTINE; CAT 3888; CD20 ANTIGEN; CD22 ANTIGEN; CD52 ANTIGEN; CLOFARABINE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; EPRATUZUMAB; EPRATUZUMAB TETRAXETAN YTTRIUM Y 90; ETOPOSIDE; FLUDARABINE; FLUOROURACIL; GEMTUZUMAB OZOGAMICIN; IFOSFAMIDE; MITOXANTRONE; MONOCLONAL ANTIBODY; MOXETUMOMAB PASUDOTOX; OBINUTUZUMAB; OFATUMUMAB; PREDNISOLONE; RITUXIMAB; SAR 3419; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADD ON THERAPY; ANTIGEN EXPRESSION; B CELL LYMPHOMA; BURKITT LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHILDHOOD LEUKEMIA; CHRONIC LYMPHATIC LEUKEMIA; CONTINUOUS INFUSION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; EVENT FREE SURVIVAL; FOLLICULAR LYMPHOMA; HUMAN; IMMUNOPHENOTYPING; INFECTION; LARGE CELL LYMPHOMA; LYMPHOCYTOPENIA; MINIMAL RESIDUAL DISEASE; MONOTHERAPY; NONHODGKIN LYMPHOMA; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; REVIEW; SALVAGE THERAPY; STEM CELL TRANSPLANTATION;

ANIMALS; ANTIBODIES, MONOCLONAL; HUMANS; LEUKEMIA, MYELOID, ACUTE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 84866310078     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12002     Document Type: Review

References (112)

1. Advani, R., Forero-Torres, A., Furman, R.R., Rosenblatt, J.D., Younes, A., Ren, H., Harrop, K., Whiting, N. & Drachman, J.G. (2009) Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma. Journal of Clinical Oncology, 27, 4371-4377.
2. Advani, A., Coiffier, B., Czuczman, M.S., Dreyling, M., Foran, J., Gine, E., Gisselbrecht, C., Ketterer, N., Nasta, S., Rohatiner, A., Schmidt-Wolf, I.G., Schuler, M., Sierra, J., Smith, M.R., Verhoef, G., Winter, J.N., Boni, J., Vandendries, E., Shapiro, M. & Fayad, L. (2010) Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. Journal of Clinical Oncology, 28, 2085-2093.
3. Al-Katib, A.M., Aboukameel, A., Mohammad, R., Bissery, M.C. & Zuany-Amorim, C. (2009) Superior antitumor activity of SAR3419 to rituximab in xenograft models for non-Hodgkin's lymphoma. Clinical Cancer Research, 15, 4038-4045.
4. Angiolillo, A.L., Yu, A.L., Reaman, G., Ingle, A.M., Secola, R. & Adamson, P.C. (2009) A phase II study of Campath-1H in children with relapsed or refractory acute lymphoblastic leukemia: a Children's Oncology Group report. Pediatric Blood & Cancer, 53, 978-983.
5. Aplenc, R., Alonzo, T.A., Gerbing, R.B., Lange, B.J., Hurwitz, C.A., Wells, R.J., Bernstein, I., Buckley, P., Krimmel, K., Smith, F.O., Sievers, E.L. & Arceci, R.J. (2008) Safety and efficacy of gemtuzumab ozogamicin in combination with chemotherapy for pediatric acute myeloid leukemia: a report from the Children's Oncology Group. Journal of Clinical Oncology, 26, 2390-3295.
6. Appelbaum, F.R., Matthews, D.C., Eary, J.F., Badger, C.C., Kellogg, M., Press, O.W., Martin, P.J., Fisher, D.R., Nelp, W.B., Thomas, E.D. & Berstein, I.D. (1992) The use of radiolabeled anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia. Transplantation, 54, 829-833.
7. Arceci, R.J., Sande, J., Lange, B., Shannon, K., Franklin, J., Hutchinson, R., Vik, T.A., Flowers, D., Aplenc, R., Berger, M.S., Sherman, M.L., Smith, F.O., Bernstein, I. & Sievers, E.L. (2005) Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia. Blood, 106, 1183-1188.
8. Balduzzi, A., Rossi, V., Corral, L., Bonanomi, S., Longoni, D., Rovelli, A., Conter, V., Biondi, A. & Uderzo, C. (2003) Molecular remission induced by gemtuzumab ozogamicin associated with donor lymphocyte infusions in t(4;11) acute lymphoblastic leukemia relapsed after transplantation. Leukemia, 17, 2247-2248.
9. Barth, M.J., Goldman, S., Zhi, J., Smith, L., Perkins, S.L., Shiramizu, B., Gross, T., Sanger, W. & Cairo, M.S. (2011) Safety and Pharmacokinetics (PK) of rituximab (R) in combination with chemotherapy in children and adolescents (C+A) with stage III/IV mature B-NHL: a Children's Oncology Group Report. Annals of Oncology, 22, iv112-iv114.
10. Barth, M.J., Hernandez-Ilizaliturri, F.J., Mavis, C., Tsai, P.C., Gibbs, J.F., Deeb, G. & Czuczman, M.S. (2012) Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma. British Journal of Haematology, 156, 490-498.
11. Berinstein, N.L., Grillo-Lopez, A.J., White, C.A., Bence-Bruckler, I., Maloney, D., Czuczman, M., Green, D., Rosenberg, J., McLaughlin, P. & Shen, D. (1998) Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Annals of Oncology, 9, 995-1001.
12. Borowitz, M.J., Shuster, J., Carroll, A.J., Nash, M., Look, A.T., Camitta, B., Mahoney, D., Lauer, S.J. & Pullen, D.J. (1997) Prognostic significance of fluorescence intensity of surface marker expression in childhood B-precursor acute lymphoblastic leukemia. A Pediatric Oncology Group study. Blood, 89, 3960-3966.
13. Bowles, J.A., Wang, S.Y., Link, B.K., Allan, B., Beuerlein, G., Campbell, M.A., Marquis, D., Ondek, B., Wooldridge, J.E., Smith, B.J., Breitmeyer, J.B. & Weiner, G.J. (2006) Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. Blood, 108, 2648-2654.
14. Brethon, B., Yakouben, K., Oudot, C., Boutard, P., Bruno, B., Jerome, C., Nelken, B., de Lumley, L., Bertrand, Y., Dalle, J.H., Chevret, S., Leblanc, T. & Baruchel, A. (2008) Efficacy of fractionated gemtuzumab ozogamicin combined with cytarabine in advanced childhood myeloid leukaemia. British Journal of Haematology, 143, 541-547.
15. Buckwalter, M., Dowell, J.A., Korth-Bradley, J., Gorovits, B. & Mayer, P.R. (2004) Pharmacokinetics of gemtuzumab ozogamicin as a single-agent treatment of pediatric patients with refractory or relapsed acute myeloid leukemia. Journal of Clinical Pharmacology, 44, 873-880.
16. Bunin, N.J., Davies, S.M., Aplenc, R., Camitta, B.M., DeSantes, K.B., Goyal, R.K., Kapoor, N., Kernan, N.A., Rosenthal, J., Smith, F.O. & Eapen, M. (2008) Unrelated donor bone marrow transplantation for children with acute myeloid leukemia beyond first remission or refractory to chemotherapy. Journal of Clinical Oncology, 26, 4326-4332.
17. Cairo, M.S., Lynch, J.C., Harrison, L., Perkins, S.L., Shiramizu, B., Gross, T.G., Sanger, W. & Goldman, S. (2010) Safety, kinetics, and outcome following rituximab (R) in combination with FAB chemotherapy in children and adolescents (C+A) with stage III/IV (Group B) and BM+/CNS+ (Group C) mature B-NHL: a Children's Oncology Group report. Journal Clinical Oncology, 28(Suppl. 15), abstract9536.
18. Cairo, M.S., Ricci, A., Bhatia, M., Duffy, D., Qualter, E.C., Morris, E., Harrison, L., Schwartz, J., Baxter Lowe, L.A., Reiter, A. & Satwani, P. (2011) Targeted immunotherpay with gemtuzumab ozogamicin during conditioning and post allogeneic stem cell transplantation in children and adolescents with poor and average risk AML/MDS. Pediatric Blood & Cancer, 57, 768.
19. Carnahan, J., Stein, R., Qu, Z., Hess, K., Cesano, A., Hansen, H.J. & Goldenberg, D.M. (2007) Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab. Molecular Immunology, 44, 1331-1341.
20. Carroll, W.L. & Raetz, E.A. (2012) Clinical and laboratory biology of childhood acute lymphoblastic leukemia. Journal of Pediatrics, 160, 10-18.
21. Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P. & Watier, H. (2002) Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood, 99, 754-758.
22. Cartron, G., Trappe, R.U., Solal-Celigny, P. & Hallek, M. (2011) Interindividual variability of response to rituximab: from biological origins to individualized therapies. Clinical Cancer Research, 17, 19-30.
23. Cheson, B.D. (2010) Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. Journal of Clinical Oncology, 28, 3525-3530.
24. Cheson, B.D. & Leonard, J.P. (2008) Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. New England Journal of Medicine, 359, 613-626.
25. Coiffier, B., Lepage, E., Briere, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., Reyes, F., Lederlin, P. & Gisselbrecht, C. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. New England Journal of Medicine, 346, 235-242.
26. Cooney-Qualter, E., Krailo, M., Angiolillo, A., Fawwaz, R.A., Wiseman, G., Harrison, L., Kohl, V., Adamson, P.C., Ayello, J., vande Ven, C., Perkins, S.L. & Cairo, M.S. (2007) A phase I study of 90yttrium-ibritumomab-tiuxetan in children and adolescents with relapsed/refractory CD20-positive non-Hodgkin's lymphoma: a Children's Oncology Group study. Clinical Cancer Research, 13, 5652s-5660s.
27. Cotter, M., Rooney, S., O'Marcaigh, A. & Smith, O.P. (2003) Successful use of gemtuzumab ozogamicin in a child with relapsed CD33-positive acute lymphoblastic leukaemia. British Journal of Haematology, 122, 687-688.
28. Creutzig, U., Harbott, J., Sperling, C., Ritter, J., Zimmermann, M., Loffler, H., Riehm, H., Schellong, G. & Ludwig, W.D. (1995) Clinical significance of surface antigen expression in children with acute myeloid leukemia: results of study AML-BFM-87. Blood, 86, 3097-3108.
29. Czuczman, M.S. & Gregory, S.A. (2010) The future of CD20 monoclonal antibody therapy in B-cell malignancies. Leukaemia & Lymphoma, 51, 983-994.
30. Czuczman, M.S., Olejniczak, S., Gowda, A., Kotowski, A., Binder, A., Kaur, H., Knight, J., Starostik, P., Deans, J. & Hernandez-Ilizaliturri, F.J. (2008) Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels. Clinical Cancer Research, 14, 1561-1570.
31. Davis, T.A., Grillo-Lopez, A.J., White, C.A., McLaughlin, P., Czuczman, M.S., Link, B.K., Maloney, D.G., Weaver, R.L., Rosenberg, J. & Levy, R. (2000) Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. Journal of Clinical Oncology, 18, 3135-3143.
32. Dayde, D., Ternant, D., Ohresser, M., Lerondel, S., Pesnel, S., Watier, H., Le Pape, A., Bardos, P., Paintaud, G. & Cartron, G. (2009) Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20. Blood, 113, 3765-3772.
33. DiJoseph, J.F., Armellino, D.C., Boghaert, E.R., Khandke, K., Dougher, M.M., Sridharan, L., Kunz, A., Hamann, P.R., Gorovits, B., Udata, C., Moran, J.K., Popplewell, A.G., Stephens, S., Frost, P. & Damle, N.K. (2004) Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood, 103, 1807-1814.
34. Dijoseph, J.F., Dougher, M.M., Armellino, D.C., Evans, D.Y. & Damle, N.K. (2007) Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia. Leukemia, 21, 2240-2245.
35. Dworzak, M.N., Schumich, A., Printz, D., Potschger, U., Husak, Z., Attarbaschi, A., Basso, G., Gaipa, G., Ratei, R., Mann, G. & Gadner, H. (2008) CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy. Blood, 112, 3982-3988.
36. FitzGerald, D.J., Wayne, A.S., Kreitman, R.J. & Pastan, I. (2011) Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates. Cancer Research, 71, 6300-6309.
37. Golay, J., Zaffaroni, L., Vaccari, T., Lazzari, M., Borleri, G.M., Bernasconi, S., Tedesco, F., Rambaldi, A. & Introna, M. (2000) Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood, 95, 3900-3908.
38. Goldenberg, D.M., Rossi, E.A., Stein, R., Cardillo, T.M., Czuczman, M.S., Hernandez-Ilizaliturri, F.J., Hansen, H.J. & Chang, C.H. (2009) Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody. Blood, 113, 1062-1070.
39. Goldman, S., Galardy, P.J., Smith, L., Perkins, S.L., Shiramizu, B., Gross, T., Sanger, W.G., Harrison, L. & Cairo, M.S. (2011) The efficacy of rasburicase and rituximab combined with FAB chemotherapy in children and adolescents with newly diagnosed stage III/IV, BM+ and CNS+ mature B-NHL: a children's oncology group report. Blood (ASH Annual Meeting Abstracts), 21, Abstract 2702.
40. Griffin, T.C., Weitzman, S., Weinstein, H., Chang, M., Cairo, M., Hutchison, R., Shiramizu, B., Wiley, J., Woods, D., Barnich, M. & Gross, T.G. (2009) A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group. Pediatric Blood & Cancer, 52, 177-181.
41. Gudowius, S., Recker, K., Laws, H.J., Dirksen, U., Troger, A., Wieczorek, U., Furlan, S., Gobel, U. & Hanenberg, H. (2006) Identification of candidate target antigens for antibody-based immunotherapy in childhood B-cell precursor ALL. Klinische Padiatrie, 218, 327-333.
42. Habermann, T.M., Weller, E.A., Morrison, V.A., Gascoyne, R.D., Cassileth, P.A., Cohn, J.B., Dakhil, S.R., Woda, B., Fisher, R.I., Peterson, B.A. & Horning, S.J. (2006) Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. Journal of Clinical Oncology, 24, 3121-3127.
43. Hagenbeek, A., Gadeberg, O., Johnson, P., Pedersen, L.M., Walewski, J., Hellmann, A., Link, B.K., Robak, T., Wojtukiewicz, M., Pfreundschuh, M., Kneba, M., Engert, A., Sonneveld, P., Flensburg, M., Petersen, J., Losic, N. & Radford, J. (2008) First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood, 111, 5486-5495.
44. Hamann, P.R., Hinman, L.M., Hollander, I., Beyer, C.F., Lindh, D., Holcomb, R., Hallett, W., Tsou, H.R., Upeslacis, J., Shochat, D., Mountain, A., Flowers, D.A. & Bernstein, I. (2002) Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjugate Chemistry, 13, 47-58.
45. Handgretinger, R., Zugmaier, G., Henze, G., Kreyenberg, H., Lang, P. & von Stackelberg, A. (2011) Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia. Leukemia, 25, 181-184.
46. Hoelzer, D. & Gokbuget, N. (2012) Chemoimmunotherapy in acute lymphoblastic leukemia. Blood Reviews, 26, 25-32.
47. Horning, S.J., Younes, A., Jain, V., Kroll, S., Lucas, J., Podoloff, D. & Goris, M. (2005) Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. Journal of Clinical Oncology, 23, 712-719.
48. Hunger, S.P., Raetz, E.A., Loh, M.L. & Mullighan, C.G. (2011) Improving outcomes for high-risk ALL: translating new discoveries into clinical care. Pediatric Blood & Cancer, 56, 984-993.
49. Hunger, S.P., Lu, X., Devidas, M., Camitta, B.M., Gaynon, P.S., Winick, N.J., Reaman, G.H. & Carroll, W.L. (2012) Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group. Journal of Clinical Oncology, 30, 1663-1669.
50. Ikemoto, N., Kumar, R.A., Ling, T.T., Ellestad, G.A., Danishefsky, S.J. & Patel, D.J. (1995) Calicheamicin-DNA complexes: warhead alignment and saccharide recognition of the minor groove. Proceedings of the National Academy of Sciences of the United States of America, 92, 10506-10510.
51. Jandula, B.M., Nomdedeu, J., Marin, P. & Vivancos, P. (2001) Rituximab can be useful as treatment for minimal residual disease in bcr-abl-positive acute lymphoblastic leukemia. Bone Marrow Transplantation, 27, 225-227.
52. Jazirehi, A.R. & Bonavida, B. (2005) Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention. Oncogene, 24, 2121-2143.
53. Jeha, S., Behm, F., Pei, D., Sandlund, J.T., Ribeiro, R.C., Razzouk, B.I., Rubnitz, J.E., Hijiya, N., Howard, S.C., Cheng, C. & Pui, C.H. (2006) Prognostic significance of CD20 expression in childhood B-cell precursor acute lymphoblastic leukemia. Blood, 108, 3302-3304.
54. Kaminski, M.S., Tuck, M., Estes, J., Kolstad, A., Ross, C.W., Zasadny, K., Regan, D., Kison, P., Fisher, S., Kroll, S. & Wahl, R.L. (2005) 131I-tositumomab therapy as initial treatment for follicular lymphoma. New England Journal of Medicine, 352, 441-449.
55. Kantarjian, H., Thomas, D., Jorgensen, J., Jabbour, E., Kebriaei, P., Rytting, M., York, S., Ravandi, F., Kwari, M., Faderl, S., Rios, M.B., Cortes, J., Fayad, L., Tarnai, R., Wang, S.A., Champlin, R., Advani, A. & O'Brien, S. (2012) Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncology, 13, 403-411.
56. Kaufmann, R., Niesvizky, R., Stadtmauer, E.A., Chanan-Khan, A., Siegel, D., Horne, H., Teoh, N., Wegener, W.A. & Goldenberg, D.M. (2009) Dose-escalation trial of milatuzumab (humainzed anti-CD74 monoclonal antibody) in multiple myeloma. Journal Clinical Oncology, 27(Suppl.), abstract8593.
57. Kennedy, G.A., Tey, S.K., Cobcroft, R., Marlton, P., Cull, G., Grimmett, K., Thomson, D. & Gill, D. (2002) Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma: a retrospective review. British Journal of Haematology, 119, 412-416.
58. Kohler, G. & Milstein, C. (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature, 256, 495-497.
59. Kreitman, R.J., Squires, D.R., Stetler-Stevenson, M., Noel, P., FitzGerald, D.J., Wilson, W.H. & Pastan, I. (2005) Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies. Journal of Clinical Oncology, 23, 6719-6729.
60. Laurenti, L., Piccioni, P., Cattani, P., Cingolani, A., Efremov, D., Chiusolo, P., Tarnani, M., Fadda, G., Sica, S. & Leone, G. (2004) Cytomegalovirus reactivation during alemtuzumab therapy for chronic lymphocytic leukemia: incidence and treatment with oral ganciclovir. Haematologica, 89, 1248-1252.
61. Law, C.L., Gordon, K.A., Collier, J., Klussman, K., McEarchern, J.A., Cerveny, C.G., Mixan, B.J., Lee, W.P., Lin, Z., Valdez, P., Wahl, A.F. & Grewal, I.S. (2005) Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40. Cancer Research, 65, 8331-8338.
62. Leonard, J.P., Coleman, M., Ketas, J., Ashe, M., Fiore, J.M., Furman, R.R., Niesvizky, R., Shore, T., Chadburn, A., Horne, H., Kovacs, J., Ding, C.L., Wegener, W.A., Horak, I.D. & Goldenberg, D.M. (2005) Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma. Journal of Clinical Oncology, 23, 5044-5051.
63. Li, Y. & Zhu, Z. (2007) Monoclonal antibody-based therapeutics for leukemia. Expert opinion on biological therapy, 7, 319-330.
64. Lin, T.S., Stock, W., Xu, H., Phelps, M.A., Lucas, M.S., Guster, S.K., Briggs, B.R., Cheney, C., Porcu, P., Flinn, I.W., Grever, M.R., Dalton, J.T. & Byrd, J.C. (2009) A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia. Leukaemia & Lymphoma, 50, 1958-1963.
65. Luqman, M., Klabunde, S., Lin, K., Georgakis, G.V., Cherukuri, A., Holash, J., Goldbeck, C., Xu, X., Kadel, E.E., 3rd, Lee, S.H., Aukerman, S.L., Jallal, B., Aziz, N., Weng, W.K., Wierda, W., O'Brien, S. & Younes, A. (2008) The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells. Blood, 112, 711-720.
66. Maloney, D.G. (2007) Follicular NHL: from antibodies and vaccines to graft-versus-lymphoma effects. Hematology/the Education Program of the American Society of Hematology, 22, 6-232.
67. Maloney, D.G., Smith, B. & Rose, A. (2002) Rituximab: mechanism of action and resistance. Seminars in Oncology, 29, 2-9.
68. Mannelli, F., Gianfaldoni, G., Intermesoli, T., Cattaneo, C., Borlenghi, E., Cortelazzo, S., Cavattoni, I., Pogliani, E.M., Fumagalli, M., Angelucci, E., Romani, C., Ciceri, F., Corti, C., Scattolin, A.M., Cortelezzi, A., Mattei, D., Audisio, E., Spinelli, O., Oldani, E., Bosi, A., Rambaldi, A. & Bassan, R. (2012) CD20 expression has no prognostic role in Philadelphia-negativeB-precursor acute lymphoblastic leukemia: new insights from the molecularstudy of minimal residual disease. Haematologica, 97, 568-571.
69. Meinhardt, A., Burkhardt, B., Zimmermann, M., Borkhardt, A., Kontny, U., Klingebiel, T., Berthold, F., Janka-Schaub, G., Klein, C., Kabickova, E., Klapper, W., Attarbaschi, A., Schrappe, M. & Reiter, A. (2010) Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin's lymphoma and Burkitt leukemia. Journal of Clinical Oncology, 28, 3115-3121.
70. Mejstrikova, E., Kalina, T., Trka, J., Stary, J. & Hrusak, O. (2005) Correlation of CD33 with poorer prognosis in childhood ALL implicates a potential of anti-CD33 frontline therapy. Leukemia, 19, 1092-1094.
71. Micallef, I.N., Maurer, M.J., Wiseman, G.A., Nikcevich, D.A., Kurtin, P.J., Cannon, M.W., Perez, D.G., Soori, G.S., Link, B.K., Habermann, T.M. & Witzig, T.E. (2011) Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma. Blood, 118, 4053-4061.
72. Miles, R.R., Cairo, M.S., Satwani, P., Zwick, D.L., Lones, M.A., Sposto, R., Abromovitch, M., Tripp, S., Angiolillo, A.L., Roman, E., Davenport, V. & Perkins, S.L. (2007) Immunophenotypic identification of possible therapeutic targets in paediatric non-Hodgkin lymphomas: a children's oncology group report. British Journal of Haematology, 138, 506-512.
73. Morschhauser, F., Illidge, T., Huglo, D., Martinelli, G., Paganelli, G., Zinzani, P.L., Rule, S., Liberati, A.M., Milpied, N., Hess, G., Stein, H., Kalmus, J. & Marcus, R. (2007) Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation. Blood, 110, 54-58.
74. Morschhauser, F., Leonard, J.P., Fayad, L., Coiffier, B., Petillon, M.O., Coleman, M., Schuster, S.J., Dyer, M.J., Horne, H., Teoh, N., Wegener, W.A. & Goldenberg, D.M. (2009) Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results. Journal of Clinical Oncology, 27, 3346-3353.
75. Morschhauser, F., Kraeber-Bodere, F., Wegener, W.A., Harousseau, J.L., Petillon, M.O., Huglo, D., Trumper, L.H., Meller, J., Pfreundschuh, M., Kirsch, C.M., Naumann, R., Kropp, J., Horne, H., Teoh, N., Le Gouill, S., Bodet-Milin, C., Chatal, J.F. & Goldenberg, D.M. (2010) High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin's lymphoma. Journal of Clinical Oncology, 28, 3709-3716.
76. Morschhauser, F., Cartron, G., Thieblemont, C., Solal-Celigny, P., Haioun, C., Bouabdallah, R., Lamy, T., Milpied, N., Gouill, S.L., Feugier, P., Wenger, M.K., Wassner-Fritsch, E., Asikanius, E. & Salles, G.A. (2011) Encouraging activity of obinutuzumab (GA101) monotherapy in relapsed/refractory agressive non-Hodgkin's lymphoma: results from a phase II study (BO20999). Blood (ASH Meeting Abstracts), 118, 3655.
77. Mossner, E., Brunker, P., Moser, S., Puntener, U., Schmidt, C., Herter, S., Grau, R., Gerdes, C., Nopora, A., van Puijenbroek, E., Ferrara, C., Sondermann, P., Jager, C., Strein, P., Fertig, G., Friess, T., Schull, C., Bauer, S., Dal Porto, J., Del Nagro, C., Dabbagh, K., Dyer, M.J., Poppema, S., Klein, C. & Umana, P. (2010) Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood, 115, 4393-4402.
78. Mussai, F., Campana, D., Bhojwani, D., Stetler-Stevenson, M., Steinberg, S.M., Wayne, A.S. & Pastan, I. (2010) Cytotoxicity of the anti-CD22 immunotoxin HA22 (CAT-8015) against paediatric acute lymphoblastic leukaemia. British Journal of Haematology, 150, 352-358.
79. Negrea, G.O., Elstrom, R., Allen, S.L., Rai, K.R., Abbasi, R.M., Farber, C.M., Teoh, N., Horne, H., Wegener, W.A. & Goldenberg, D.M. (2011) Subcutaneous injections of low-dose veltuzumab (humanized anti-CD20 antibody) are safe and active in patients with indolent non-Hodgkin's lymphoma. Haematologica, 96, 567-573.
80. Nguyen, K., Devidas, M., Cheng, S.C., La, M., Raetz, E.A., Carroll, W.L., Winick, N.J., Hunger, S.P., Gaynon, P.S. & Loh, M.L. (2008) Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study. Leukemia, 22, 2142-2150.
81. Olejniczak, S.H., Hernandez-Ilizaliturri, F.J., Clements, J.L. & Czuczman, M.S. (2008) Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased Bax and Bak expression. Clinical Cancer Research, 14, 1550-1560.
82. Pagano, L., Fianchi, L., Caira, M., Rutella, S. & Leone, G. (2007) The role of Gemtuzumab Ozogamicin in the treatment of acute myeloid leukemia patients. Oncogene, 26, 3679-3690.
83. Pawluczkowycz, A.W., Beurskens, F.J., Beum, P.V., Lindorfer, M.A., van de Winkel, J.G., Parren, P.W. & Taylor, R.P. (2009) Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX. Journal of immunology, 183, 749-758.
84. Perkins, S.L., Lones, M.A., Davenport, V. & Cairo, M.S. (2003) B-Cell non-Hodgkin's lymphoma in children and adolescents: surface antigen expression and clinical implications for future targeted bioimmune therapy: a children's cancer group report. Clinical Advances in Hematology and Oncology, 1, 314-317.
85. Pfreundschuh, M., Trumper, L., Osterborg, A., Pettengell, R., Trneny, M., Imrie, K., Ma, D., Gill, D., Walewski, J., Zinzani, P.L., Stahel, R., Kvaloy, S., Shpilberg, O., Jaeger, U., Hansen, M., Lehtinen, T., Lopez-Guillermo, A., Corrado, C., Scheliga, A., Milpied, N., Mendila, M., Rashford, M., Kuhnt, E. & Loeffler, M. (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncology, 7, 379-391.
86. Pohlen, M., Gerth, H.U., Liersch, R., Koschmieder, S., Mesters, R.M., Kessler, T., Appelmann, I., Muller-Tidow, C. & Berdel, W.E. (2011) Efficacy and toxicity of a rituximab and methotrexate based regimen (GMALL B-ALL/NHL 2002 protocol) in Burkitt's and primary mediastinal large B-cell lymphoma. American Journal of Hematology, 86, E61-E64.
87. Quintas-Cardama, A., Wierda, W. & O'Brien, S. (2010) Investigational immunotherapeutics for B-cell malignancies. Journal of Clinical Oncology, 28, 884-892.
88. Radford, J., Davies, A., Cartron, G., Morschhauser, F., Salles, G.A., Marcus, R.E., Wenger, M.K., Asikanius, E., Wassner-Fritsch, E. & Vitolo, U. (2011) Obinutuzumab (GA101) in combination with FC or CHOP in patients with relapsed or refractory follicular lymphoma: final results of the phase I GAUDI study (BO21000). Blood (ASH Annual Meeting Abstracts), 118, 270.
89. Raetz, E.A., Borowitz, M.J., Devidas, M., Linda, S.B., Hunger, S.P., Winick, N.J., Camitta, B.M., Gaynon, P.S. & Carroll, W.L. (2008) Reinduction platform for children with first marrow relapse of acute lymphoblastic leukemia: a Children's Oncology Group Study [corrected]. Journal of Clinical Oncology, 26, 3971-3978.
90. Raetz, E.A., Cairo, M.S., Borowitz, M.J., Xiaomin Lu, P., Devidas, M., Reid, J.M., Goldenberg, D.M., Wegener, W.A., Whitlock, J.A., Adamson, P.C., Hunger, S.P. & Carroll, W.L. (2011) Reinduction chemoimmunotherapy with epratuzumab in relapsed Acute lymphoblastic leukemia (ALL) in children, adolescents and young adults: results from children's oncology group (COG) study ADVL04P2. Blood (ASH Annual Meeting Abstracts), 118, 573.
91. Roman, E., Cooney, E., Harrison, L., Militano, O., Wolownik, K., Hawks, R., Foley, S., Satwani, P., Unal, E., Bhatia, M., Bradley, B., Del Toro, G., George, D., Garvin, J., van de Ven, C. & Cairo, M.S. (2005) Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia. Clinical Cancer Research, 11, 7164s-7170s.
92. Salles, G., Morschhauser, F., Lamy, T., Milpied, N., Thieblemont, C., Tilly, H., Bieska, G., Carlile, D. & Cartron, G. (2009) (abstract)) Phase I study of RO5072759 (GA101) in patients with relapsed/refractory CD20+ non-Hodgkin lymphoma (NHL). Blood (ASH Annual Meeting Abstracts), 114, 1704.
93. Satwani, P., Bhatia, M., Garvin, J.H. Jr., George, D., Dela Cruz, F., Le Gall, J., Jin, Z., Schwartz, J., Duffy, D., van de Ven, C., Foley, S., Hawks, R., Morris, E., Baxter-Lowe, L.A. & Cairo, M.S. (2012) A phase I study of gemtuzumab ozogamicin (GO) in combination with busulfan and cyclophosphamide (Bu/Cy) and allogeneic stem cell transplantation in children with poor-risk CD33(+) AML: a new targeted immunochemotherapy myeloablative conditioning (MAC) regimen. Biology of Blood Marrow Transplantation, 18, 324-329.
94. Sehn, L.H., Goy, A., Offner, F.C., Martinelli, G., Friedberg, J., Lasserre, S.F., Fine, G. & Press, O.W. (2011) Randomized phase II trial comparing GA101 (Obinutuzumab) with rituximab in patients with relapsed CD20 Indolent B-cell non-Hodgkin lymphoma: preliminary analysis of the GAUSS study. Blood (ASH Annual Meeting Abstracts), 118, 269.
95. Sievers, E.L., Appelbaum, F.R., Spielberger, R.T., Forman, S.J., Flowers, D., Smith, F.O., Shannon-Dorcy, K., Berger, M.S. & Bernstein, I.D. (1999) Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood, 93, 3678-3684.
96. Sievers, E.L., Larson, R.A., Stadtmauer, E.A., Estey, E., Lowenberg, B., Dombret, H., Karanes, C., Theobald, M., Bennett, J.M., Sherman, M.L., Berger, M.S., Eten, C.B., Loken, M.R., van Dongen, J.J., Bernstein, I.D. & Appelbaum, F.R. (2001) Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. Journal of Clinical Oncology, 19, 3244-3254.
97. Smith, M.A. (2009) Update on developmental therapeutics for acute lymphoblastic leukemia. Current Hematologic Malignancy Reports, 4, 175-182.
98. Stasi, R., Evangelista, M.L., Buccisano, F., Venditti, A. & Amadori, S. (2008) Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. Cancer Treatment Reviews, 34, 49-60.
99. Teeling, J.L., Mackus, W.J., Wiegman, L.J., van den Brakel, J.H., Beers, S.A., French, R.R., van Meerten, T., Ebeling, S., Vink, T., Slootstra, J.W., Parren, P.W., Glennie, M.J. & van de Winkel, J.G. (2006) The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. Journal of immunology, 177, 362-371.
100. Thomas, D.A., O'Brien, S., Faderl, S., Garcia-Manero, G., Ferrajoli, A., Wierda, W., Ravandi, F., Verstovsek, S., Jorgensen, J.L., Bueso-Ramos, C., Andreeff, M., Pierce, S., Garris, R., Keating, M.J., Cortes, J. & Kantarjian, H.M. (2010) Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. Journal of Clinical Oncology, 28, 3880-3889.
101. Topp, M.S., Kufer, P., Gokbuget, N., Goebeler, M., Klinger, M., Neumann, S., Horst, H.A., Raff, T., Viardot, A., Schmid, M., Stelljes, M., Schaich, M., Degenhard, E., Kohne-Volland, R., Bruggemann, M., Ottmann, O., Pfeifer, H., Burmeister, T., Nagorsen, D., Schmidt, M., Lutterbuese, R., Reinhardt, C., Baeuerle, P.A., Kneba, M., Einsele, H., Riethmuller, G., Hoelzer, D., Zugmaier, G. & Bargou, R.C. (2011a) Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. Journal of Clinical Oncology, 29, 2493-2498.
102. Topp, M.S., Goekbuget, N., Zugmaier, G., Viardot, A., Stelljes, M., Neumann, S., Horst, H.A., Reichle, A., Marks, R.E., Brueggemann, M., Ritgen, M., Klappers, P., Mergen, N., Goebeler, M.-E., Einsele, H., Hoelzer, D. & Bargou, R. (2011b) Anti-CD19 BiTE blinatumomab induces high complete remission rate in adult patients with relapsed B-precursor ALL: updated results of an ongoing phase II trial. Blood (ASH Annual Meeting Abstracts), 118, 252.
103. de Vries, M.J., Veerman, A.J. & Zwaan, C.M. (2004) Rituximab in three children with relapsed/refractory B-cell acute lymphoblastic leukaemia/Burkitt non-Hodgkin's lymphoma. British Journal of Haematology, 125, 414-415.
104. Wayne, A.S., Kreitman, R.J., Findley, H.W., Lew, G., Delbrook, C., Steinberg, S.M., Stetler-Stevenson, M., Fitzgerald, D.J. & Pastan, I. (2010) Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial. Clinical Cancer Research, 16, 1894-1903.
105. Wayne, A.S., Bhojwani, D., Silverman, L.B., Richards, K., Stetler-Stevenson, M., Shah, N.N., Jeha, S., Pui, C.H., Buzoianu, M., FitzGerald, D.J., Kreitman, R.J., Ibrahim, R. & Pastan, I. (2011) A novel anti-CD22 immunotoxin, moxetumomab pasudotox: phase I study in pediatric acute lymphoblastic leukemia (ALL). Blood (ASH Annual Meeting Abstracts), 118, 248.
106. Wierda, W.G., Kipps, T.J., Mayer, J., Stilgenbauer, S., Williams, C.D., Hellmann, A., Robak, T., Furman, R.R., Hillmen, P., Trneny, M., Dyer, M.J., Padmanabhan, S., Piotrowska, M., Kozak, T., Chan, G., Davis, R., Losic, N., Wilms, J., Russell, C.A. & Osterborg, A. (2010) Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. Journal of Clinical Oncology, 28, 1749-1755.
107. Witzig, T.E., Gordon, L.I., Cabanillas, F., Czuczman, M.S., Emmanouilides, C., Joyce, R., Pohlman, B.L., Bartlett, N.L., Wiseman, G.A., Padre, N., Grillo-Lopez, A.J., Multani, P. & White, C.A. (2002) Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Journal of Clinical Oncology, 20, 2453-2463.
108. Woods, W.G., Neudorf, S., Gold, S., Sanders, J., Buckley, J.D., Barnard, D.R., Dusenbery, K., DeSwarte, J., Arthur, D.C., Lange, B.J. & Kobrinsky, N.L. (2001) A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. Blood, 97, 56-62.
109. Xia, M.Q., Hale, G. & Waldmann, H. (1993) Efficient complement-mediated lysis of cells containing the CAMPATH-1 (CDw52) antigen. Molecular Immunology, 30, 1089-1096.
110. Zwaan, C.M., Reinhardt, D., Corbacioglu, S., van Wering, E.R., Bokkerink, J.P., Tissing, W.J., Samuelsson, U., Feingold, J., Creutzig, U. & Kaspers, G.J. (2003a) Gemtuzumab ozogamicin: first clinical experiences in children with relapsed/refractory acute myeloid leukemia treated on compassionate-use basis. Blood, 101, 3868-3871.
111. Zwaan, C.M., Reinhardt, D., Jurgens, H., Huismans, D.R., Hahlen, K., Smith, O.P., Biondi, A., van Wering, E.R., Feingold, J. & Kaspers, G.J. (2003b) Gemtuzumab ozogamicin in pediatric CD33-positive acute lymphoblastic leukemia: first clinical experiences and relation with cellular sensitivity to single agent calicheamicin. Leukemia, 17, 468-470.
112. Zwaan, C.M., Reinhardt, D., Zimmerman, M., Hasle, H., Stary, J., Stark, B., Dworzak, M., Creutzig, U. & Kaspers, G.J. (2010) Salvage treatment for children with refractory first or second relapse of acute myeloid leukaemia with gemtuzumab ozogamicin: results of a phase II study. British Journal of Haematology, 148, 768-776.